Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.56, No.4, p.348-352, 2009 |
||
Title: TNF-α-308 promotor polymorphism in patients with chronic obstructive pulmonary disease and lung cancer | ||
Author: M. M. STANKOVIC, A. R. NESTOROVIC, A. M. TOMOVIC, N. D. PETROVIC-STANOJEVIC, M. S. ANDJELIC-JELIC, V. B. DOPUDJA-PANTIC, Lj. M. NAGORNI-OBRADOVIC, M. M. MITIC-MILIKIC, D. P. RADOJKOVIC | ||
Abstract: Chronic obstructive pulmonary disease (COPD) and lung cancer (LC) are a major cause of morbidity and mortality worldwide. In both diseases airways inflammation plays an important role. Functional promoter polymorphism, at the position -308, of tumor necrosis factor (TNF)-α represents attractive potential susceptibilty marker for both diseases. In order to investigate the role of this polymorphism in COPD and LC, a case-control study was performed. The patient groups consisted of 97 subjects with COPD and 70 subjects with LC, while the control group encompassed 102 subjects. Results of our study showed significant decrease of heterozygote for TNF-α-308*1/*2 gene variant in COPD group in comparison to controls (p=0.043). According to our results heterozygous carriers of TNF-α-308*1/*2 polymorphism had a 2.3-fold decreased risk for COPD development (OR=0.44, 95%CI=0.20-0.97). In patients with lung cancer we also observed a trend of decreased distribution of TNF-α-308*1/*2 heterozygotes, but statistical significance was not achieved. To our knowledge, this is the first study implicating decreased frequency of TNF-α-308*1/*2 gene variant in patients with COPD and LC. Although these results need to be confirmed on larger cohort, they represent a new and interesting finding, not reported in other populations tested so far. |
||
Keywords: COPD, lung cancer, TNF-α-308 promoter polymorphism | ||
Year: 2009, Volume: 56, Issue: 4 | Page From: 348, Page To: 352 | |
doi:10.4149/neo_2009_04_348 |
||
|
download file |
|